BICO Group
45.6 SEK +2.89%2 investors are following this company
BICO Group is active in medical technology. The company specializes in bio convergence and provides technology, products, and services for biology. With a focus on the application areas bioprinting, multi-omics, cell line development, and diagnostics, the company develops and markets technology that enables researchers to grow cells in 3D environments, conduct drug screening, and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries.
Revenue
2.25B
EBIT %
-64.44 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
BICO
Daily low / high price
44.48 / 45.86
SEK
Market cap
3.22B SEK
Turnover
4.99M SEK
Volume
110K
Latest videos
Financial calendar
Interim report
07.05.2024
General meeting
20.05.2024
Interim report
20.08.2024
Interim report
13.11.2024
Annual report
19.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Erik Gatenholm | 13.6 % | 20.5 % |
Sartorius Lab Holding GmbH | 10.1 % | 8.5 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Anders Fogelberg appointed as Chief Commercial Officer for BICO Group AB (publ)
Notice to attend the Annual General Meeting in BICO Group AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools